⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2193910 | 0.84 | LMNA (0.50) | — | |
| SCHEMBL11688424 | 0.81 | TBXAS1 (0.43) | — | |
| SCHEMBL1855099 | 0.80 | — | — | |
| SCHEMBL9387523 | 0.80 | — | — | |
| SCHEMBL28737088 | 0.80 | — | — | |
| SCHEMBL5844802 | 0.79 | TBXAS1 (0.48) | — | |
| SCHEMBL628995 | 0.79 | LMNA (0.44) | — | |
| SCHEMBL688511 | 0.77 | TBXAS1 (0.52) | — | |
| SCHEMBL1701144 | 0.77 | — | — | |
| SCHEMBL5844804 | 0.77 | TBXAS1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106278890-A | A kind of synthetic method of 1 (1 halogenated cyclopropyl) formic acid ester compound | 西安近代化学研究所 | 2017-01-04 | — | — | CN | disclosed |
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1313725-B1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2007-04-11 | — | — | EP | disclosed |
| EP-1492772-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS AS ANTITUMOR AGENTS | SCHERING CORPORATION (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20040176403-A1 | Methods for treating multidrug resistance | JOHNSON WILLIAM W (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1453513-A1 | USE OF FPT INHIBITORS AND AT LEAST TWO ANTINEOPLASTIC AGENTS IN THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040122018-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION | 2004-06-24 | — | — | US | disclosed |
| US-6703400-B2 | ADMINISTERING BENZO(5,6) CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVE AS ANTITUMOR AGENT; P-GLYCLOPROTEIN INHIBITOR | SCHERING CORPORATION | 2004-03-09 | — | — | US | disclosed |
| US-20040006087-A1 | Method of treating cancer using FPT inhibitors and antineoplastic agents | SCHERING CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-20030229099-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | PHARMACOPEIA DRUG DISCOVERY | 2003-12-11 | — | — | US | disclosed |
| US-20030216422-A1 | Methods for treating multidrug resistance | SCHERING CORPORATION | 2003-11-20 | — | — | US | disclosed |
| WO-2003072549-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS AS ANTITUMOR AGENTS | SCHERING CORPORATION (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003047586-A1 | USE OF FPT INHIBITORS AND AT LEAST TWO ANTINEOPLASTIC AGENTS IN THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-1313725-A1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020198216-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | PHARMACOPEIA DRUG DISCOVERY | 2002-12-26 | — | — | US | disclosed |
| WO-2002018368-A1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-1999062865-A1 | HALOETHYL-2-[ (2,6-DICHLOROPHENYL) AMINO] PHENYLACETOXYACETATE DERIVATIVES AND THEIR USE AS AN INTERMEDIATE TO SYNTHESIZE ACECLOFENAC | KIM JAE CHUL (KR) | 1999-12-09 | — | — | WO | disclosed |